BBIO vs BFLY
BridgeBio Pharma, Inc. vs Butterfly Network, Inc. — AI-powered side-by-side comparison
BBIO
BridgeBio Pharma, Inc.
65
Insufficient Data
VS
BFLY
Butterfly Network, Inc.
67
Buy
| Metric | BBIO | BFLY |
|---|
| AI Score |
65
|
67
|
| Price |
$83.71
|
$9.36
|
| P/E Ratio |
-23.38×
|
-32.38×
|
| ROE |
35.1%
|
-39.3%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
93.1%
|
51.1%
|
| Debt / Equity |
-0.99×
|
0.10×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
56.9
|
66.4
|
| Beta |
0.983
|
2.084
|
| Expected Upside |
—
|
—
|
AI Committee View
Current Innellis committee reasoning for BBIO versus BFLY.
BFLY leads by 2 points.
BFLY scores 67/100 (Buy) versus BBIO at 65/100 (Insufficient Data).
BBIO Committee View
67% agreement
3 analysts
Some positive signals exist — vix regime is low -- calm backdrop supports risk-taking — but they are not yet strong enough to justify a Buy. The committee is monitoring for confirmation.
Bull Case
- Price structure making higher highs and higher lows — Technical
- Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
- VIX regime is low -- calm backdrop supports risk-taking — Macro
Bear Case
- MACD histogram negative -- bearish momentum — Technical
- Price structure (LH_LL) contradicts the uptrend -- mixed signals — Technical
BFLY Committee View
67% agreement
6 analysts
The primary driver is revenue growing 28.1% yoy -- genuine top-line momentum. The main limiting factor is roe of only -38.4% -- cheap may mean cheap for a reason. The committee is constructive but not yet at full conviction.
Bull Case
- Revenue growing 28.1% YoY -- genuine top-line momentum — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- ROE of only -38.4% -- cheap may mean cheap for a reason — Value
- Bollinger bandwidth of 52.6% signals elevated volatility — Risk